Stay updated with breaking news from Slate Development. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
AstraZeneca’s Evusheld (tixagevimab and cilgavimab, formerly AZD7442) retains neutralisation activity against the emerging Omicron BA.4 and BA.5 (BA.4/5) variants, says preclinical pseudovirus assay data from the University of Oxford.
EVUSHELD™ long-acting antibody combination retains neutralizing activity against Omicron variants including BA.2 in new independent studies - read this article along with other careers information, tips and advice on BioSpace
Middle-East Arab News and Opinion - Asharq Al-Awsat is the world’s premier pan-Arab daily newspaper, printed simultaneously each day on four continents in 14 cities
This is the first data looking at the impact of AstraZeneca’s Evusheld treatment on “cousins” of the Omicron variant following a recent global spike in cases.
(RTTNews) - British drug major AstraZeneca PLC (AZN, AZN.L) Monday said that data from new independent studies showed that EVUSHELD (tixagevimab c...